Clinical trials
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) clinical trials
Below are recruiting squamous cell carcinoma head and neck cancer (hnscc) clinical trials, each written for real people, not researchers. We’re tracking 185 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06108089Recruiting
Hypoxia imaging for head and neck cancer treatment planning
This study uses a special MRI scan to measure oxygen levels in your head and neck tumor. The goal is to learn if this scan can help doctors choose the best treatment plan for you.
Salt Lake City, UtahAges 18 years+ - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Irvine, CaliforniaAges 18 years+ - NCT07276399RecruitingPhase 3
Study of amivantamab plus standard care for head and neck cancer
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
Chandler, ArizonaAges 18 years+ - NCT04892173RecruitingPhase 3
Radiation plus a tumor injection, with or without cetuximab
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Birmingham, AlabamaAges 60 years+ - NCT07219212RecruitingPhase 1
New drug with chemo and radiation for advanced head and neck cancer
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Birmingham, AlabamaAges 18–74 - NCT06239220RecruitingPhase 2
Combination immunotherapy for advanced head and neck cancer
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Margate, FloridaAges 18 years+ - NCT04754321RecruitingPhase 1
Test immunotherapy with salvage surgery and IORT for head and neck cancer
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Columbus, OhioAges 18 years+ - NCT07026474RecruitingPhase 3
Re-radiation plus immunotherapy for recurrent head and neck cancer
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
ChemnitzAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT04722523RecruitingPhase 1
Cemiplimab plus chemo and other immune treatment for head and neck cancer
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
Basking Ridge, New JerseyAges 18 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Tampa, FloridaAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT07398664RecruitingPhase 2
H101 virus plus TACE for recurrent head and neck cancer
This trial tests combining a cancer-killing virus (H101) with a procedure that delivers chemo directly to the tumor (TACE) for people with advanced head and neck cancers that have not responded to at least two standard treatments. It aims to see if this combination can help shrink tumors and improve outcomes.
Chengdu, SichuanAges 18–80 - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT06496178RecruitingPhase 3
Petosemtamab for advanced head and neck cancer after prior treatment
This trial tests a new drug called petosemtamab for people with head and neck cancer that has gotten worse after immunotherapy and platinum chemotherapy. The goal is to see if it works better than the standard single-drug options available.
Mobile, AlabamaAges 18 years+ - NCT03406247RecruitingPhase 2
Immunotherapy after salvage surgery for head and neck cancer
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
Villejuif, Val De MarneAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT07214987RecruitingPhase 2
PDT with immunotherapy and chemo for head and neck cancer
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Boston, MassachusettsAges 18 years+ - NCT04099290Recruiting
Blood DNA test in newly diagnosed head and neck cancer
This study looks at “circulating tumor DNA” (tumor DNA found in blood) in people with newly diagnosed, locally advanced head and neck squamous cell cancer. Researchers want to see how the blood DNA levels relate to the cancer and how it may guide treatment after surgery.
Chapel Hill, North CarolinaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04470024RecruitingPhase 1
Testing a vaccine plus immunotherapy for recurrent head and neck cancer
This early-phase (Phase 1b) study tests a vaccine designed to train the immune system to fight head and neck squamous cell carcinoma, plus standard immunotherapy. It may help some people by boosting the body’s anti-cancer immune response, but it mainly focuses on safety and finding the best approach.
Portland, OregonAges 18 years+
Hear when a new Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell carcinoma head and neck cancer (hnscc)?
- Yes. Clin2 currently lists 185 recruiting squamous cell carcinoma head and neck cancer (hnscc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell carcinoma head and neck cancer (hnscc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell carcinoma head and neck cancer (hnscc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Cancer
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Resectable Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.